Effect of L-dopa, oxyferriscorbone and ferrous iron on in vivo lipid peroxidation

  • P. Dostert
  • M. Strolin Benedetti
  • E. Frigerio
Full Papers


We report here on an in vivo model of lipid peroxidation, which consists in measuring the amount of ethane present in the exhaled air after the oral administration of linolenic acid to rats. This model was used to study the effect of L-dopa, oxyferriscorbone (OFS), a ferri-ferro-complex, and ferrous iron, this latter alone or associated with ascorbic acid, on lipid peroxidation. Intravenous or oral administration of L-dopa did not influence the amount of ethane produced by an oral dose of 1.25 ml/kg of linolenic acid. Intravenous injection of OFS (50 mg/kg) as well as the co-injection of FeSO4, 7 H2O (15 mg/ kg) and ascorbic acid (15 mg/kg) were found to decrease the amount of ethane produced by 1.25 ml/kg of linolenic acid given orally, whereas the same dose of ferrous sulfate alone was ineffective. The possible causes which might underlie the absence of effects of L-dopa and ferrous iron and the partial inhibition of lipid peroxidation by OFS and ferrous ions associated with ascorbic acid are discussed.


L-dopa ferrous iron lipid peroxidation Parkinson's disease oxyferriscorbone 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer W, Birkmayer JGD (1986) Iron, a new aid in the treatment of Parkinson patients. J Neural Transm 67: 287–292Google Scholar
  2. Birkmayer W, Birkmayer JGD (1988) Iron: a new approach in the treatment of Parkinson's disease. In: Belmaker RH, Sandler M, Dahlström A (eds) Progress in catecholamine research. Part C. Clinical aspects. Alan R Liss, New York, pp 25–28Google Scholar
  3. Burk RF, Ludden TM (1989) Exhaled alkanes as indices of in vivo lipid peroxidation. Biochem Pharmacol 38: 1029–1032Google Scholar
  4. Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neurone senescence. J Neural Transm 19: 89–103Google Scholar
  5. Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with dopamine turnover. Ann Neurol 26: 689–690Google Scholar
  6. Dexter T, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1986) Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet ii: 639–640Google Scholar
  7. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989a) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830–1836Google Scholar
  8. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989b) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381–389Google Scholar
  9. Dordain G, Vernay D, Leroux S, Gonce M, Strolin Benedetti M, Dostert P (1988) Might iron be safe in Parkinson's disease? New Trends Clin Neuropharmacol 2: 152Google Scholar
  10. Fornstedt B, Carlsson A (1989) A marked rise in 5-S-cysteinyl-dopamine levels in guineapig striatum following reserpine treatment. J Neural Transm 76: 155–161Google Scholar
  11. Frankel EN (1982) Volatile lipid oxidation products. Prog Lipid Res 22: 1–33Google Scholar
  12. Graham DG (1984) Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese toxicity and Parkinson's disease. Neurotoxicology 5: 83–96Google Scholar
  13. Graham DG, Tiffany SM, Bell WR, Gutknecht WF (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro. Mol Pharmacol 14: 644–653Google Scholar
  14. Halliwell B, Gutteridge JMC (1985) Free radicals in biology and medicine. Clarendon Press, OxfordGoogle Scholar
  15. Halliwell B, Gutteridge JMC (1986) Oxygen free radicals and iron in relation to biology and medicine. Arch Biochem Biophys 246: 501–514Google Scholar
  16. Knight JA, Hopfer SM, Reid MC, Wong SH-Y, Sunderman FW (1986) Ethene (ethylene) and ethane exhalation in Ni (II)-treated rats, using an improved rebreathing apparatus. Ann Clin Lab Sci 16: 386–394Google Scholar
  17. Lawrence GD, Cohen G (1982) Ethane exhalation as an index of in vivo lipid peroxidation: concentrating ethane from a breath collection chamber. Anal Biochem 122: 283–290Google Scholar
  18. Leaf A, Weber PC (1988) Cardiovascular effects of n-3 fatty acids. N Engl J Med 318: 549–557Google Scholar
  19. Mansuy D, Sassi A, Dansette PM, Plat M (1986) A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiol thione. Biochem Biophys Res Commun 135: 1015–1021Google Scholar
  20. Marczenko Z (1976) Spectrophotometric determination of elements. Ellis Horwood, New York, pp 309–312Google Scholar
  21. McDonald GB, Saunders DR, Weidman M, Fisher L (1980) Portal venous transport of long-chain fatty acids absorbed from rat intestine. Am J Physiol 239: G141-G150Google Scholar
  22. Minotti G, Aust SD (1987) The requirement for iron (III) in the initiation of lipid peroxidation by iron (II) and hydrogen peroxide. J Biol Chem 262: 1098–1104Google Scholar
  23. Rausch W-D, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50: 202–208Google Scholar
  24. Riederer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, gluthatione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515–520Google Scholar
  25. Riely CA, Cohen G, Lieberman M (1974) Ethane evolution: a new index of lipid peroxidation. Science 183: 208–210Google Scholar
  26. Richard C, Guichard JP, Strolin Benedetti M, Dostert P (1987) Effect of MAO inhibitors on “in vivo” lipid peroxidation. Pharmacol Toxicol 60 [Suppl 1]: 38Google Scholar
  27. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, Jenner P, Marsden CD (1989) A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692–697Google Scholar
  28. Slivka A, Cohen G (1985) Hydroxyl radical attack on dopamine. J Biol Chem 280: 15468–15472Google Scholar
  29. Slivka A, Kang J, Cohen G (1986) Hydroxyl radicals and the toxicity of oral iron. Biochem Pharmacol 35: 553–556Google Scholar
  30. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205Google Scholar
  31. Strolin Benedetti M, Dostert P (1989) Effect of selective monoamine oxidase substrates and inhibitors on lipid peroxidation and their possible involvement in affective disorders. In: Lerer B, Gershon S (eds) New directions in affective disorders. Springer, Berlin Heidelberg New York Tokyo, pp 156–160Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • P. Dostert
    • 1
  • M. Strolin Benedetti
    • 1
  • E. Frigerio
    • 1
  1. 1.Research and Development - Erbamont GroupFarmitalia Carlo ErbaMilanItaly

Personalised recommendations